Romeu, MD, Guasch, M, Ezcurra, G, Lambea-Gil, A, Ramos-Pachón, A, Martínez-Domeño, A, Prats-Sanchez, L, Fernandez-Vidal, JM, Toscano-Prat, C, Martí-Fàbregas, J, Martínez-González, JP, Fernández-Cadenas, I, Cardona, P, Rodriguez-Villatoro, N, Rodríguez-Vázquez, A, Gomis, M, Xuclà-Ferrarons, T, Rodrìguez-Campello, A, Cánovas, D, Seró, L, Purroy, F, Salvat-Plana, M, Abilleira, S, Camps-Renom, P. EXTERNAL VALIDATION OF TWO PREDICTIVE SCORES FOR HEMORRHAGIC TRANSFORMATION FOLLOWING ENDOVASCULAR THROMBECTOMY IN A POPULATIONBASED STUDY. International Journal of Stroke. 2025; 20DOI:. PMID:. IF:8.700(Q1/1D).

Eggers, C, Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Lauria, G, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, van Doorn, P, Lewis, R. ADHERE plus trial interim analysis: long-term safety and efficacy of efgartigimod in chronic inflammatory demyelinating polyneuropathy (CIDP). NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105858. PMID:. IF:2.800(Q2/5D).

Toscano, A, Bratkovic, D, Claeys, K, Díaz-Manera, J, Mozaffar, T, Roberts, M, Schoser, B, van der Ploeg, A, Jain, V, Holdbrook, F, Moore, P, O'Brien-Prince, K, Kishnani, P. 208-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease treated from PROPEL baseline: muscle function and biomarkers. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105857. PMID:. IF:2.800(Q2/5D).

Kleefeld, F, Vigo, EG, Gamboa, JT, Funke, A, Roos, A, Mensch, A, Gehrig, J, Ruck, T, Mossakowski, A, Llanso, L, Bortolani, S, Torchia, E, Casal-Dominguez, M, Pinal-Fernandez, I, Mammen, A, Tasca, G, Preusse, C, Stenzel, W. Brachio-cervical inflammatory myopathy: evidence for a distinct form of inflammatory muscle disease. NEUROMUSCULAR DISORDERS. 2025; 53DOI:10.1016/j.nmd.2025.105458. PMID:. IF:2.800(Q2/5D).